RBC Capital Sticks to Its Buy Rating for UBS Group AG (UBS)
Elevate Your Investing Strategy:
Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Reingen covers the Financial sector, focusing on stocks such as UBS Group AG, Deutsche Bank AG, and BNP Paribas. According to TipRanks, Reingen has an average return of 19.8% and a 71.81% success rate on recommended stocks.
In addition to RBC Capital, UBS Group AG also received a Buy from DZ BANK AG's Philipp Haessler in a report issued on August 1. However, on July 31, Morgan Stanley maintained a Sell rating on UBS Group AG (NYSE: UBS).
Based on UBS Group AG's latest earnings release for the quarter ending June 30, the company reported a quarterly revenue of $18.32 billion and a net profit of $2.4 billion. In comparison, last year the company earned a revenue of $11.85 billion and had a net profit of $1.14 billion
Based on the recent corporate insider activity of 11 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of UBS in relation to earlier this year.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
CTV News
42 minutes ago
- CTV News
What a Russia-Ukraine ceasefire deal could mean for global markets
Stock price information is displayed on screens as they hang above the Paris stock exchange, operated by Euronext NV, in La Defense business district in Paris, France. LONDON — World markets are watching closely as U.S. President Donald Trump and Russian President Vladimir Putin meet in Alaska later on Friday to seal a possible ceasefire agreement in Ukraine. This is a conflict that sparked an energy shock, sent food prices soaring, battered European assets and cut Russia's economy off from much of the Western world. Details and the longevity of any agreement will be key, and for now investors are on standby. Ukraine's government bonds - key indicators of the mood - in recent days have largely stalled at a still-distressed 55 cents on the dollar. 'The big issue will be, of course, that even if we get a ceasefire, how sustainable is that?' said Zurich Insurance Group's chief markets strategist Guy Miller. Here is a summary of how Europe's biggest conflict since the Second World War has shaped markets and what impact a ceasefire agreement could have. Europe hurt Europe's reliance on cheap Russian gas meant its economy and stock market were ill-equipped to handle surging energy prices, and Germany's economy, Europe's industrial powerhouse, stagnated. Stocks were broadly punished, with sectors reliant on low energy prices, such as industrials and chemicals, notably hit. European banks also took a drubbing but have since recovered as those exposed to Russia cut ties. It has not been all doom and gloom and the European index is not far off March's record high. Aerospace and defense stocks have had a supercharged rally since February 2022, with gains ranging from over 600 per cent for Leonardo to over 1,500 per cent for Rheinmetall. 'If the fighting stops in Ukraine, I'd expect defense stocks to come off a little bit but I think the fundamental reason why defense stocks have rallied is still there,' said Toni Meadows, CIO at BRI Wealth Management. 'If Putin is still there and Trump is still there, then the need for Europe to spend on defense is still there.' Heated The invasion triggered a surge in European energy prices. Brent crude rose as much as 30 per cent to US$139 a barrel, while natural gas prices soared nearly 300 per cent to record highs. Crude subsided in the following months. But Dutch futures, the regional benchmark for natural gas, soared as Europe scrambled for an alternative to the Russian gas that fed over 40 per cent of total demand. Europe has since become increasingly reliant on U.S. super-chilled liquefied natural gas. The European Union has committed to boosting its purchases of U.S. crude, gas and coal from around $75 billion in 2024 to $250 billion per year to 2027, under a new U.S. trade deal - a figure most experts say is unrealistic. Oil and gas prices are below 2022 peaks, but they are higher than five years ago, up 50 per cent and 300 per cent, respectively. Genie out of the bottle Following the COVID-19 pandemic, the war ensured the inflation genie was well out of its bottle as energy and food prices soared while agricultural exports from Russia and Ukraine - two leading grain exporters - were disrupted. Central banks backtracked on the notion that an inflation spike was 'transitory' and aggressive interest rate hikes followed. Since late 2022, inflation and rates have come down in big economies and focus shifted to U.S. tariffs. High food prices remain a concern, especially for developing economies. World food commodity prices rose in July to their highest in over two years, according to the United Nations' Food and Agriculture Organization. 'If Ukraine could operate normally as an economy, that would help food prices around the world,' said April LaRusse, head of investment specialists at Insight Investment. Ukraine and Russia Ukraine's economy was battered by the war. The country was forced to restructure $20 billion of its government debt last year as it could no longer afford the repayments given the demands of the conflict. Its bonds then rallied on hopes that a re-elected Trump would broker a peace deal but plunged following increasingly ugly exchanges between Trump and Ukraine's Volodymyr Zelenskyy that culminated in February's infamous Oval Office meeting. The bonds recovered some ground again this week. Russia's economy also contracted after the West introduced sweeping sanctions but soaring defense spending led to a rebound in 2023 and 2024. After jacking up rates to combat the subsequent inflation spike though, some Russian officials now warn of recession risks. Russia's rouble sank to a record low soon after the invasion, but rebounded to seven-year highs later in 2022 as imports dried up. It is up nearly 40 per cent against the dollar this year. Russia and China meanwhile now do more of their trade in the yuan, which has overtaken the dollar as Russia's most traded foreign currency. Currencies upended The war hit the euro, which fell almost six per cent against the U.S> dollar in 2022 as the economic impact was felt. Analysts say any improving sentiment created by a ceasefire could help the euro, but note that other factors, such as monetary policy were also key. 'The euro might benefit, but we wouldn't see this as a game changer for the currency,' said Frederique Carrier, head of investment strategy for RBC Wealth Management in the British Isles and Asia. While safe-havens such as the dollar and Swiss franc benefited, the conflict shaped currencies in other ways. Analysts say the use of sanctions against Russia and a decision by the West to freeze some $300 billion of Russian state assets in 2022 has accelerated de-dollarisation, in short, efforts by countries to decrease reliance on the dollar. (Reporting by Amanda Cooper, Marc Jones, Dhara Ranasinghe, Samuel Indyk, additional reporting by Alexander Marrow, Compiled by Dhara Ranasinghe; Editing by Tomasz Janowski)
Globe and Mail
42 minutes ago
- Globe and Mail
AstraZeneca Rides Oncology Momentum With Blockbuster and New Drugs
AstraZeneca AZN is one of the leading drugmakers in the oncology space. Oncology sales (comprising around 43% of AstraZeneca's total revenues) rose 18% in the second quarter of 2025, generating $6.3 billion in sales. In the first half of 2025, the Oncology segment generated almost $12 billion in revenues, which rose 16% year over year. The strong oncology performance was driven by medicines such as Tagrisso, Lynparza, Imfinzi, Calquence and Enhertu (in partnership with Daiichi Sankyo). AstraZeneca also has a profit-sharing deal with Merck MRK for Lynparza. AstraZeneca is working on strengthening its oncology product portfolio through label expansions of existing products and progressing oncology pipeline candidates. A key new cancer drug approval was that of Truqap for HR-positive, HER2-negative (HR+ HER2-) breast cancer. The drug has seen a robust launch, recording sales of $302 million in the first half of 2025, driven by demand growth in the second-line biomarker-altered population. AstraZeneca expects further growth for Truqap to be driven by increased uptake within the PIK3CA population and additional global launches. AstraZeneca and partner Daiichi's drug, Datroway, was approved by the FDA for HR+ HER2- breast cancer in January and for EGFR-mutated non-small cell lung cancer (NSCLC) in June this year. Datroway witnessed encouraging early launch signals in the United States for the breast cancer indication in the first half, recording sales of $14 million. Important late-stage oncology candidates in AstraZeneca's pipeline are camizestrant (HR+ HER2- metastatic breast cancer), volrustomig (several types of cancers), sonesitatug vedotin (advanced or metastatic gastric or GEJ adenocarcinoma) and surovatamig (previously untreated follicular lymphoma). Regulatory applications seeking approval of Imfinzi for early-stage gastric and gastroesophageal junction cancers are under regulatory review. AstraZeneca expects continued growth of its oncology medicines in the second half, particularly Tagrisso, Enhertu, and Merck-partnered Lynparza and Imfinzi, despite the incremental impact of the Part D redesign. Our estimates for AstraZeneca's total oncology portfolio suggest a CAGR of around 11.1% over the next three years. Competition in the Oncology Space Other large players in the oncology space are Pfizer PFE, Merck and Bristol-Myers BMY. Pfizer boasts a strong portfolio of approved cancer medicines like Xtandi, Lorbrena, and the Braftovi-Mektovi combination. Pfizer's oncology revenues grew 9% in the first half of 2025. The addition of Seagen in 2023 also strengthened its position in oncology by adding four antibody-drug conjugates (ADCs) — Adcetris, Padcev, Tukysa and Tivdak. Pfizer also has a robust pipeline of cancer candidates with a focus on multiple modalities, including small molecules, ADCs and immuno-oncology biologics. Merck's key oncology medicines are PD-L1inhibitor, Keytruda and PARP inhibitor, Lynparza, which it markets in partnership with AstraZeneca. Keytruda, approved for several types of cancer, alone accounts for around 50% of Merck's pharmaceutical sales. Keytruda's sales rose 6.6% to $15.1 billion in the first half of 2025. Bristol-Myers' key cancer drug is PD-L1inhibitor, Opdivo, which accounts for around 20% of its total revenues. Opdivo's sales rose 9% to $4.82 billion in the first half of 2025. See our %%CTA_TEXT%% report – free today! 7 Best Stocks for the Next 30 Days Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report AstraZeneca PLC (AZN): Free Stock Analysis Report Bristol Myers Squibb Company (BMY): Free Stock Analysis Report Pfizer Inc. (PFE): Free Stock Analysis Report Merck & Co., Inc. (MRK): Free Stock Analysis Report
Globe and Mail
42 minutes ago
- Globe and Mail
Mining Stocks Outpace Gold's Historic Rally as Sector Primes for Breakout
Issued on behalf of Lake Victoria Gold Ltd. VANCOUVER – News Commentary – The precious metals market is experiencing an extraordinary alignment of bullish catalysts that analysts believe could drive gold prices to unprecedented levels, as record-breaking momentum pushes the metal above US$3,400 per ounce. Leading Wall Street institutions are revising their price targets upward in remarkable synchronization, with J.P. Morgan projecting US$4,000 by mid-2026 while UBS analysts issue strong endorsements for mining equities. The convergence of safe-haven buying, unprecedented central bank purchases, and escalating geopolitical tensions is creating conditions for an extended precious metals supercycle that could redefine market dynamics. Companies positioned to benefit from this exceptional environment include Lake Victoria Gold (TSXV: LVG) (OTCQB: LVGLF), Gold Royalty Corp. (NYSE-American: GROY), Osisko Development Corp. (NYSE: ODV) (TSXV: ODV), Allied Gold Corporation (NYSE: AAUC) (TSX: AAUC), and Orla Mining Ltd. (NYSE-American: ORLA) (TSX: OLA). This gold surge differs markedly from previous cycles due to the exceptional performance of mining stocks, with the VanEck Gold Miners ETF climbing more than 40% year-to-date versus gold's own substantial gains. Leading investment banks are indicating a paradigm shift in their approach to valuing gold producers, as UBS anticipates a "stronger for longer gold price environment" that should catalyze increased share buybacks and consolidation activity throughout the sector. The combination of strong operating cash flows, disciplined capital deployment, and sustained commodity strength is generating what market observers characterize as ideal conditions for mining equity revaluation, especially among firms with proven production capabilities and defined growth trajectories. Lake Victoria Gold (TSXV: LVG) (OTCQB: LVGLF) stands on the verge of a transformation that could redefine its trajectory from explorer to producer, as the Nyati Resources processing facility reaches final commissioning stages. Located directly on one of LVG's Tembo licences adjacent to Barrick's sprawling Bulyanhulu Mine, the plant represents more than infrastructure—it's the catalyst for unlocking near-term cash flow from two advanced gold projects. Recent site inspections reveal a facility nearing operational readiness, with commissioning now targeted within the next four to six weeks. The existing 120 tonne-per-day carbon-in-pulp circuit operates under full licensing, while a substantially larger 500+ tpd line approaches completion. Combined capacity will exceed 600 tpd, supported by dual regrind mills, extended leach circuits, and grid-tied power systems with backup generation. Stockpiles await on the ROM pad as final equipment undergoes dry testing. "It was impressive to see the scale and quality of construction firsthand,' David Scott, Managing Director Tanzania & Director of Lake Victoria Gold, who captured the momentum during his latest site visit. 'The Nyati team has delivered a well-engineered plant with strong attention to detail across all critical circuits. With commissioning just weeks away, the site is clearly in the final stages of readiness. This facility will play a key role in enabling our development strategy at Tembo and beyond." The processing pathway accelerates LVG's dual-project advancement strategy. At the fully permitted Imwelo Gold Project, positioned just 12 km from AngloGold Ashanti's Geita mine, a strategic 7,750m drill program will targets Area C's highest-grade zones. The campaign splits between 3,750m of grade control drilling for immediate mine planning and 4,000m testing mineralized extensions, building on intercepts including 6.8m at 14.6 g/t gold from 33m and 7m at 3.22 g/t from 27m. "We've designed this program to maximize Imwelo's short-term production readiness while extending the upside case," said Marc Cernovitch, President and CEO of Lake Victoria Gold. "The drill data will help us finalize early mine scheduling, validate pit design, and potentially unlock high-grade extensions. With Area C now fully defined as our initial production zone, we're making meaningful progress toward Tanzania's next gold producer." Simultaneously, Tembo's Ngula 1 target advances through 3,000m of up coming drilling, targeting shallow, high-grade zones ideal for early Nyati processing. Previous hits of 28.57 g/t over 3m from 54m and 17.23 g/t over 4m from 19m underscore the potential for rapid cash generation ahead of full Imwelo development. Recent Barrick presentations highlight intensive exploration across the region, including systematic drilling programs on ground formerly held by LVG —providing more validation of the district's broader geological potential. Strategic upside extends through LVG's exposure to up to US$45 million in milestone payments from the 2021 asset sale to Barrick's Bulyanhulu operation. Financial runway strengthens through recently announced private placements totaling up to C$7.5 million, earmarked for development, exploration, and working capital across both projects. With plant commissioning weeks away, drilling programs about to commence, and funding secured, LVG positions itself uniquely in Tanzania's gold landscape—a company transitioning from exploration potential to production reality within one of Africa's most prolific mining districts. In other industry developments and happenings in the market include: Gold Royalty Corp. (NYSE-American: GROY) has achieved a stunning transformation to positive free cash flow while delivering record Q2 2025 results that validate its royalty-focused business model. The company reported record revenue of $3.8 million from 1,346 gold equivalent ounces and record Adjusted EBITDA of $2.4 million, representing a remarkable 100% year-over-year revenue increase. Total Revenue, Land Agreement Proceeds and Interest reached $4.4 million, underscoring the power of Gold Royalty's diversified approach to precious metals exposure. "We have truly reached an exciting inflection point, achieving positive free cash flow for the quarter and half year, as well as record revenues and cash margins in both periods," said David Garofalo, Chairman and CEO of Gold Royalty. The company maintained its 2025 guidance of 5,700-7,000 GEOs despite setbacks at some operations, with production expected to be weighted toward H2 2025 as key assets including Côté, Vareš, and Borborema reach full production capacity. With a portfolio of over 200 assets and a clear pathway to 23,000-29,000 GEOs by 2029, Gold Royalty has established itself as a capital-efficient vehicle for precious metals exposure without operational risk. The company's royalty generator model continues expanding, having added 50 new royalties since 2021, positioning it for sustained growth as commodity prices remain elevated and mining operations mature across its diversified asset base. Osisko Development Corp. (NYSE: ODV) (TSXV: ODV) has secured transformational financing following strong Q2 2025 operational results that position the company for construction of its flagship Cariboo Gold Project in British Columbia. The company reported $6.9 million in revenues from selling 1,393 gold ounces at its Tintic Project and maintained $46.3 million in cash at quarter-end, providing operational stability while advancing major development milestones. The highlight came with Osisko Development's announcement of a US$450 million credit facility with Appian Capital and a concurrent US$195 million private placement, providing the funding package necessary to construct Cariboo. The project's optimized feasibility study showcases compelling economics with an after-tax NPV of $943 million and IRR of 22.1% at US$2,400/oz gold, targeting average annual production of 190,000 ounces over a 10-year mine life. "The publication of the Notice of Intent marks a significant milestone for our South Railroad project, continuing the process towards receipt of final permits," said Sean Roosen, Chairman and CEO of Osisko Development. With permitting advancing, construction preparation underway, and financing secured, the company has positioned itself as a near-term gold producer with multiple development pathways across its North American asset portfolio. Allied Gold Corporation (NYSE: AAUC) (TSX: AAUC) has delivered solid production growth despite temporarily elevated costs, producing 91,017 ounces of gold in Q2 2025—an 8.3% increase from the previous quarter that keeps the company on track to meet annual guidance. Sales of 81,103 ounces generated strong cash flows, though timing of shipments resulted in 9,914 ounces produced in Q2 being sold in July for $30 million in Q3 revenue. The company reported Q2 AISC of $2,343 per ounce, reflecting strategic waste removal at Agbaou to access higher-grade ore in H2 2025 and operational enhancements across its portfolio. Management expects significant improvement with H2 AISC projected at approximately $1,850 per ounce based on higher production, normalized shipment timing, and reduced stripping costs. "In the first half of the year, the Company continued implementing improvements to its operations, and undertook a series of operational enhancements and strategic initiatives aimed at delivering a materially stronger going forward, beginning in the second half of the year," said Peter Maroni, Chairman and CEO of Allied Gold. With the Kurmuk Project 90% complete in engineering and the Sadiola Phase 1 expansion progressing on schedule, Allied is building the foundation to become a 600,000-ounce annual producer by 2026 while maintaining $218.6 million in cash and strong financial flexibility. Orla Mining Ltd. (NYSE-American: ORLA) (TSX: OLA) has achieved a major permitting milestone while demonstrating operational resilience through strong Q2 2025 financial results that included record quarterly production of 77,811 ounces and adjusted net earnings of $64.2 million. The U.S. Bureau of Land Management published the Notice of Intent for the South Railroad Project, formally initiating the NEPA review process and positioning the company to receive final permits within 12 months. Orla reported revenue growth and robust cash generation that enabled $30 million in debt repayment while maintaining $215.4 million in cash. Despite a pit wall event at Camino Rojo that temporarily suspended mining, the company implemented a comprehensive remediation plan and revised 2025 guidance to 265,000-285,000 ounces, demonstrating operational discipline and risk management capabilities. "The publication of the Notice of Intent marks a significant milestone for our South Railroad project, continuing the process towards receipt of final permits. South Railroad is the next pillar in Orla's organic growth strategy toward annual gold production of 500,000 ounces," said Jason Simpson, CEO of Orla Mining. With successful integration of the Musselwhite Mine acquisition, advancing permitting at South Railroad, and continued exploration success at Zone 22, Orla has positioned itself for sustained production growth across three key jurisdictions. cs@ (250) 999-4849 DISCLAIMER: Nothing in this publication should be considered as personalized financial advice. We are not licensed under securities laws to address your particular financial situation. No communication by our employees to you should be deemed as personalized financial advice. Please consult a licensed financial advisor before making any investment decision. This is a paid advertisement and is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. is owned by Media Corp. ('BAY'). BAY has been paid a fee for Lake Victoria Gold Ltd. advertising and digital media from a shareholder of the Company (333,333 unrestricted shares). There may be 3rd parties who may have shares of Lake Victoria Gold Ltd., and may liquidate their shares which could have a negative effect on the price of the stock. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. Because of this conflict, individuals are strongly encouraged to not use this publication as the basis for any investment decision. The owner/operator of 'BAY' reserve the right to buy and sell, and will buy and sell shares of Lake Victoria Gold Ltd. at any time without any further notice commencing immediately and ongoing. We also expect further compensation as an ongoing digital media effort to increase visibility for the company, no further notice will be given, but let this disclaimer serve as notice that all material, including this article, which is disseminated by BAY has been approved by Lake Victoria Gold Ltd. Technical information relating to Lake Victoria Gold Ltd. has been reviewed and approved by David Scott, Pr. Sci. Nat., a Qualified Person as defined by National Instrument 43-101. Mr. Scott is a registered member of the South African Council for Natural Scientific Professions (SACNASP) and is a Director of Lake Victoria Gold Ltd., and therefore is not independent of the Company; this is a paid advertisement, we currently own shares of Lake Victoria Gold Ltd. and will buy and sell shares of the company in the open market, or through private placements, and/or other investment vehicles. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between the any predictions and actual results. Always consult a licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.
